Merck KGaA, Darmstadt, Germany (XTRA:MRK), a leading global science and technology company, has agreed to acquire Mirus Bio from Gamma Biosciences for $600 million in cash, marking a significant transaction in the biotechnology and advanced therapy bioprocessing sector. This acquisition is set to enhance Merck’s capabilities in the fast-growing cell and gene therapy market. Mirus […]
Pfizer Inc. (NYSE: PFE) announced a significant breakthrough in hemophilia treatment with the U.S. Food and Drug Administration’s approval of BEQVEZ (fidanacogene elaparvovec-dzkt), a pioneering gene therapy for adults with moderate to severe hemophilia B. This one-time treatment, designed to enable patients to internally produce the blood-clotting factor IX (FIX), offers a potential life-changing alternative […]
RTW Biotech Opportunities Ltd, an investment company listed on the London Stock Exchange and specialized in the life sciences sector, is proud to announce its participation in the Series C financing round of Obsidian Therapeutics, Inc. The round successfully raised $160.5 million, a testament to the high growth potential seen in Obsidian’s innovative approaches to […]
Merck has embarked on a monumental investment venture, injecting more than €300 million into the construction of a new Bioprocessing Production Center located in Daejeon, South Korea. This initiative stands as the most significant investment by Merck’s Life Science business sector in the Asia-Pacific region to date, underscoring the company’s dedication to expanding its operations […]
Ginkgo Bioworks, a leader in cell programming and biosecurity, announced its acquisition of Proof Diagnostics, a trailblazer in life sciences tools, diagnostics, and computational discovery. Specializing in genome engineering tools for therapeutic and diagnostic applications, Proof Diagnostics has been at the forefront of developing a smart, portable system for detecting infectious diseases and other medical […]
Andelyn Biosciences, Inc., a leading Contract Development and Manufacturing Organization (CDMO) specializing in cell and gene therapy, has announced a significant partnership with Armatus Bio to expedite the manufacturing of a gene therapy treatment for Charcot-Marie-Tooth Type 1A (CMT1A). This rare genetic neurological disease, characterized by disability and potentially fatal complications, currently lacks approved therapies. […]
bluebird bio, Inc., a pioneer in the biotechnology industry, has announced the U.S. commercial infrastructure for LYFGENIA (lovotibeglogene autotemcel, also known as lovo-cel), an FDA-approved gene therapy for patients 12 years and older with sickle cell disease and a history of vaso-occlusive events (VOEs). The launch of LYFGENIA, leveraging bluebird’s experience in delivering ex vivo […]
XyloCor Therapeutics, a clinical-stage biopharmaceutical company focusing on novel gene therapies for cardiovascular diseases, has revealed encouraging 12-month data from the Phase 2 section of its Phase 1/2 EXACT trial. The trial is evaluating the safety and preliminary efficacy of its lead gene therapy candidate, XC001 (encoberminogene rezmadenovec), in refractory angina patients. The data show […]
Hyderabad-based pharmaceutical company Laurus Labs has announced a significant investment in Immunoadoptive Cell Therapy (lmmunoACT), an advanced cell and gene therapy firm. The deal, valued at INR 80 crores, will increase Laurus Labs’ stake in ImmunoACT to 33.86% on a fully diluted basis. This strategic move is expected to provide ImmunoACT with the necessary capital […]
German-based biotechnology company CSL Behring has received conditional marketing authorization (CMA) from the European Commission (EC) for its Hemgenix (etranacogene dezaparvovec) indicated for the treatment of hemophilia B in adults. Hemgenix (also known as CSL222, previously known as AMT-061) is an adeno-associated virus five (AAV5)-based gene therapy intended to be given as a one-time treatment […]